SCHEMBL4833434

SCHEMBL4833434

Cc1nc(=O)n2nc(-c3ccccc3Cl)c(I)c2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.43
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
KDM5B Q9UGL1 1/20 0.37
XDH P47989 1/20 0.37
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
HAVCR2 Q8TDQ0 1/20 0.35
PARP1 P09874 2/20 0.35
CNR2 P34972 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
KMT2A Q03164 1/20 0.34
CDK4 P11802 1/20 0.34
CCND1 P24385 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843180 0.81 XDH (0.47) CNR1KDM4ETP53POLBKDM5B
SCHEMBL4834205 0.69 XDH (0.43) KDM4EPOLBKDM5BXDHMAPK13
SCHEMBL4837574 0.69 CNR1 (0.50) CNR1TP53XDHMAPK13MAPK12
SCHEMBL4840877 0.69 KMT2A (0.37) CNR1TP53HAVCR2CNR2SMN1; SMN2
SCHEMBL5386879 0.68 ALDH1A1 (0.46) KDM4ETP53POLBSMN1; SMN2KMT2A
SCHEMBL4836834 0.67 DPP4 (0.47) CNR1KDM4ETP53POLBKDM5B
SCHEMBL6517585 0.65 CNR1 (0.43) CNR1POLBKMT2AHSD11B1
SCHEMBL1387751 0.62 MAPK14 (0.53) CNR1KDM4EMAPK13MAPK12MAPK11
SCHEMBL5375243 0.62 DPP4 (0.37) KDM4ETP53XDHSMN1; SMN2NPC1
SCHEMBL20076033 0.62 TP53 (0.47) CNR1KDM4ETP53POLBKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329658-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC (US) 2008-02-12 US disclosed
EP-1592691-A1 PYRAZOLO[1,5-A][1,3,5]TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2005-11-09 EP disclosed
WO-2004069837-A1 PYRAZOLO`1,5-A!`1,3,5!TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157839-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157839-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 CNR1 1/4885KDM4E 3361/4885TP53 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.